ABBV-438 Clinical Trials (2026): 1 Studies for Multiple Myeloma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 ABBV-438 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Multiple Myeloma) and 127 total planned enrollment. 1 ABBV-438 clinical trial is actively recruiting at 5 U.S. sites across 4 states. Most recent activity: NCT07409246 (Nov 2031).
Where to Participate: All ABBV-438 Trial Sites in the U.S. (5 sites across 4 states)
Every actively recruiting ABBV-438trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | City of Hope National Medical Center /ID# 280273 | Duarte91010 | NCT07409246 | Map |
| CA | City of Hope - Orange County Lennar Foundation Cancer Center /ID# 279067 | Irvine92618 | NCT07409246 | Map |
| CO | Colorado Blood Cancer Institute /ID# 280275 | Denver80218 | NCT07409246 | Map |
| GA | City Of Hope - Atlanta. /ID# 280294 | Newnan30265 | NCT07409246 | Map |
| MI | START Midwest /ID# 279035 | Grand Rapids49546 | NCT07409246 | Map |
ABBV-438 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting ABBV-438 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07409246 | MMA Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM) | P1 | Multiple Myeloma | 127 | Feb 2026 |
All ABBV-438 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07409246 | MM | A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM) | P1 | recruiting | 127 | AbbVie | Feb 2026 |
ABBV-438 clinical trials: frequently asked questions
- How many ABBV-438 clinical trials are there?
- 1 ABBV-438 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are ABBV-438 clinical trials recruiting in 2026?
- Yes — 1 ABBV-438 trial is actively recruiting in 2026, with 5 U.S. sites across 4 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is ABBV-438 being studied for?
- ABBV-438 is being studied for Multiple Myeloma. The trials are grouped by indication on this page.
- What phase is ABBV-438 in?
- ABBV-438 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors ABBV-438 clinical trials?
- The lead sponsor across the most ABBV-438 trials is AbbVie. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming ABBV-438as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: